Pricing Log in Create free account
Saturday 17 October 2026 Export DGX’s income statement to Excel — free account

Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 14.7%, free cash flow grew 5.28% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

235.00 4.15 −1.74%
Market cap
$26.4B
P/E
24.6×
Fwd P/E
20.8×
Dividend yield
1.44%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Quest Diagnostics Incorporated 10-Q filed Jul 23, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:16 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 22, 2026: 32 added · 4 removed · 29 modified; 25 with only figures updated

  1. Added · Senior Notes Offering and Repayment of Existing Senior Notes

    In May 2026, we completed a senior notes offering consisting of $500 million aggregate principal amount of 5.00% senior notes due June 2036 (the "2036 Senior Notes"), which were issued at an original issue discount of $6 million. On June 1, 2026, the net proceeds from the 2036 Senior Notes and cash on hand were used to repay in full at maturity the outstanding indebtedness under our $500 million of 3.45% senior notes.

64 more changes in this Item, word by word, in Powerpack.

Powerpack